Company news
Omeros Corporation news in 2025
Omeros Corporation's news releases, calls and decks from 2025, newest first.
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
December 26, 2025
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
December 24, 2025
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
December 1, 2025
Omeros Corporation Reports Third Quarter 2025 Financial Results
November 13, 2025
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
November 11, 2025
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
October 16, 2025
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
October 15, 2025
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
September 2, 2025
Omeros Corporation Reports Second Quarter 2025 Financial Results
August 14, 2025
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
August 11, 2025
D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering
July 31, 2025
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
July 25, 2025
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
June 27, 2025
Omeros Announces Webcast Details for Annual Meeting of Shareholders
June 24, 2025
Omeros Corporation Reports First Quarter 2025 Financial Results
May 15, 2025
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
May 12, 2025
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
May 12, 2025
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
May 6, 2025
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
April 10, 2025
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
April 8, 2025
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
March 31, 2025
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
March 26, 2025
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
March 21, 2025
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
March 13, 2025
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
February 20, 2025
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
February 13, 2025
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
February 9, 2025
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
January 15, 2025